CHRS Q4 2018 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$219M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$27M

Operating Income

-$61M

Net Income

-$63M

EPS (Diluted)

$-0.92

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$48M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$99M

Total Liabilities

$138M

Stockholders' Equity

-$39M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$27M	-$31M	+13.8%
Operating Income	-$61M	-$46M	-30.2%
Net Income	-$63M	-$49M	-27.6%